Since 2012, our SEIS funds and EIS funds have made over 221 investments into 59 companies, with 50 still in the portfolio. We invest up to £150k of seed funding into SEIS companies, and typically up to £300k of EIS follow-on funding (click here to learn about the SEIS and EIS schemes and their tax reliefs). We also regularly give our fund investors the opportunity to make their own follow-on co-investments at our monthly presentations.
Many of our companies are located in and around Oxford, so that our UK team can get actively involved with assisting them during their early years. Beyond that, our only portfolio constraint is that each company must incorporate genuinely novel science or technology: we invest in "proper" start-ups that can disrupt existing sectors or even create whole new ones. The SEIS and EIS schemes offer significant downside protection and loss reliefs to de-risk these opportunities.
For full descriptions, progress updates, and current valuations of our portfolio companies, please see our Latest Quarterly Report.
New Investments (Q3 & Q4 2023)
Chambertech wants to reduce the duration (by half) and increase the efficiency of
treating heart arrhythmia.
Designer Carbon Material is producing endohedral fullerenes (hollow spheres of carbon atoms) containing a single atom of another element, for quantum computing applications
Theraport develops engineered exosomes to improve and transform drug delivery.
Animal Dynamics is adapting the techniques and structures of animals to create more efficient vehicles. SEIS shareholders secured a 14x after tax return.
No Longer in the Portfolio